Panitumumab plus mFOLFOX6 therapy for colorectal cancer patients of RAS wild with potential resectable metastases in relation to early tumor shrinkage

ABSTRACT: Primary outcome(s): Early tumor shrinkage(at the point of 8 weeks)

DISEASE(S): Colorectal Cancer With Potential Resectable Metastases

PROVIDER: 2628185 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR